

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 Jul 2026

### Evaluation of the Effect of Intravenous Hydrocortison Administration on post-Anesthesi General Sore Throat

#### Protocol summary

##### Study aim

To determine and compare the incidence and severity of post-anesthetic sore throat in the recovery room after full consciousness, as well as at 6 and 24 hours following extubation, between the intervention and control groups.

##### Design

This study will be conducted as a randomized double-blind clinical trial. The intervention group will receive intravenous hydrocortisone at a dose of 1.5 mg/kg before induction of anesthesia, while the control group will receive normal saline. The severity of postoperative sore throat will be assessed and recorded using the Visual Analog Scale (VAS) upon admission to the recovery room and at 6 and 24 hours after tracheal extubation.

##### Settings and conduct

A randomized double-blind parallel-group controlled clinical trial

##### Participants/Inclusion and exclusion criteria

participants: Patients scheduled for general anesthesia and endotracheal intubation. Inclusion criteria: Patient consent, age 18 to 65 years without underlying disease. Exclusion criteria: Hypersensitivity to hydrocortisone, difficulty in intubation, history of chronic sore throat, recent upper respiratory tract infection.

##### Intervention groups

Intervention group: Participants will receive intravenous hydrocortisone at a dose of 1.5 mg/kg diluted in a 10-cc syringe administered as an intravenous infusion over 10 minutes before induction of general anesthesia. Control group: Participants will receive 10 cc of normal saline administered as an intravenous infusion over 10 minutes before induction of general anesthesia.

##### Main outcome variables

Severity of postoperative sore throat measured using the Visual Analog Scale (VAS) upon admission to the recovery room and at 6 and 24 hours after tracheal extubation.

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20251231068511N1**

Registration date: **2026-07-21, 1405/04/30**

Registration timing: **retrospective**

Last update: **2026-07-21, 1405/04/30**

Update count: **0**

##### Registration date

2026-07-21, 1405/04/30

##### Registrant information

##### Name

Sare Raeisi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 54 3322 8409

##### Email address

sare4884@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2026-06-04, 1405/03/14

##### Expected recruitment end date

2026-07-20, 1405/04/29

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

|                                                                                                            |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Evaluation of the Effect of Intravenous Hydrocortison Administration on post-Anesthesi General Sore Throat |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Public title</b>                                                                                        | Evaluation of The Effeect of Intravenous Hydrocortisone Administration on posst-Anesthesia General Sore Throat                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Purpose</b>                                                                                             | Prevention                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Inclusion/Exclusion criteria</b>                                                                        | <p><b>Inclusion criteria:</b><br/>The patient must be willing to participate in the study<br/>The patient must be between 18 and 65 years old no underlying condition<br/>The patient must be candidate for general anesthesia</p> <p><b>Exclusion criteria:</b><br/>Drug allergy to Hydrocortison<br/>Muiltiple attempts at intubation<br/>History of chronic sore throat<br/>History of recent Upper Respiratory Tract Infection</p>                                                                                                                                                                                                  |
| <b>Age</b>                                                                                                 | From <b>18 years</b> old to <b>65 years</b> old                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Gender</b>                                                                                              | Both                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Phase</b>                                                                                               | 3                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| <b>Groups that have been masked</b>                                                                        | <ul style="list-style-type: none"> <li>• Participant</li> <li>• Investigator</li> <li>• Outcome assessor</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| <b>Sample size</b>                                                                                         | Target sample size: <b>56</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| <b>Randomization (investigator's opinion)</b>                                                              | Randomized                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| <b>Randomization description</b>                                                                           | Participants will be randomly assigned to the intervention or control group using simple randomization. Randomization will be performed using a random number table until the required sample size for each group is reached. Even numbers will be assigned to the hydrocortisone intervention group, and odd numbers will be assigned to the control group.                                                                                                                                                                                                                                                                            |
| <b>Blinding (investigator's opinion)</b>                                                                   | Double blinded                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| <b>Blinding description</b>                                                                                | The study will be conducted as a double-blind trial, where both the participants and the outcome assessor are blinded to the treatment allocation. Allocation concealment will be ensured using sequentially numbered, opaque, sealed envelopes (SNOSE). The randomization sequence will be generated first; then, the allocation will be written on a card and placed inside each envelope in the generated order. The envelopes will be numbered sequentially on the outside and placed in a box. Upon enrollment, each participant will receive the next available envelope in the sequence to determine their treatment assignment. |
| <b>Placebo</b>                                                                                             | Used                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| <b>Assignment</b>                                                                                          | Parallel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| <b>Other design features</b>                                                                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| <b>Secondary Ids</b>                                                                                       | empty                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Ethics committees</b>                                                                                   | <p><b>1</b></p> <p><b>Ethics committee</b></p> <p><b>Name of ethics committee</b><br/>Ethics Committee of Zahedan University of Medical Sciences</p> <p><b>Street address</b><br/>Persian Gulf Boulevard, Dr.Hesabi Square University of Medical Sciences Campus, Central Headquarters Building, Second Floor.</p> <p><b>City</b><br/>Zahedan</p> <p><b>Province</b><br/>Sistan-va-Balouchestan</p> <p><b>Postal code</b><br/>9816743463</p> <p><b>Approval date</b><br/>2025-02-08, 1403/11/20</p> <p><b>Ethics committee reference number</b><br/>IR.ZAUMS.REC.1403.450</p>                                                           |
| <b>Health conditions studied</b>                                                                           | <p><b>1</b></p> <p><b>Description of health condition studied</b><br/>Evaluation of the Effect of Intravenous Hydrocortisone Administration on Postoperative Sore Throat Following General Anesthesia</p> <p><b>ICD-10 code</b></p> <p><b>ICD-10 code description</b></p>                                                                                                                                                                                                                                                                                                                                                               |
| <b>Primary outcomes</b>                                                                                    | <p><b>1</b></p> <p><b>Description</b><br/>Severity score of postoperative sore throat following tracheal extubation after general anesthesia</p> <p><b>Timepoint</b><br/>Assessment of postoperative sore throat severity upon admission to the recovery room ,and at 6 and 24 hours after tracheal extubation</p> <p><b>Method of measurement</b><br/>Based on the Visual Analogue Scale pain scale</p>                                                                                                                                                                                                                                |
| <b>Secondary outcomes</b>                                                                                  | empty                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| <b>Intervention groups</b>                                                                                 | <p><b>1</b></p> <p><b>Description</b><br/>Intervantion group:Participants in this group will receive</p>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

intravenous hydrocortisone at a dose of 1.5 mg/kg diluted in a 10-cc syringe administered as an intravenous infusion over 10 minutes before induction of general anesthesia.

**Category**

Prevention

**2**

**Description**

Control group: Participants in this group will receive 10 cc of normal saline administered as an intravenous infusion over 10 minutes before induction of general anesthesia.

**Category**

Prevention

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Ali ibn Abitaleb hospital and Khatam Al-Anbia hospital

**Full name of responsible person**

Asadullah Shakeri

**Street address**

Persian Gulf Highway, opposite Imam Khomeini Mosque, Ali ibn Abi Taleb hospital.

**City**

Zahedan

**Province**

Sistan-va-Balouchestan

**Postal code**

9816743111

**Phone**

+98 54 3329 5570

**Email**

info@zaums.ac.ir

**Web page address**

http://zaums.ac.ir

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Zahedan University of Medical Sciences

**Full name of responsible person**

Saeideh Sarhaddi

**Street address**

Persian Gulf Boulevard, Dr. Hesabi Square, University of Medical Sciences Campus, Building No. 1, Second Floor

**City**

Zahedan

**Province**

Sistan-va-Balouchestan

**Postal code**

9816743463

**Phone**

+98 915 190 4706

**Email**

info@zaums.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Zahedan University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin**

**Type of organization providing the funding**

Academic

**Person responsible for general inquiries**

**Contact**

**Name of organization / entity**

Zahedan University of Medical Sciences

**Full name of responsible person**

Sareh Raeisi

**Position**

Student

**Latest degree**

A Level or less

**Other areas of specialty/work**

General Practitioner

**Street address**

Persian Gulf Boulevard, Dr. Hesabi Square, University of Medical Sciences Campus,

**City**

Zahedan

**Province**

Sistan-va-Balouchestan

**Postal code**

9914787697

**Phone**

+98 915 952 2512

**Email**

sare4884@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Zahedan University of Medical Sciences

**Full name of responsible person**

Sareh Raeisi

**Position**

Student

**Latest degree**

A Level or less

**Other areas of specialty/work**

General Practitioner

**Street address**

Second Floor,Central Headquarters  
Building,Univercity of Medical Sciences  
Campus,Dr.Hesabi Square,Zahedan

**City**

Zahedan

**Province**

Sistan-va-Balouchestan

**Postal code**

9816743463

**Phone**

+98 54 3337 2113

**Email**

sare4884@gmail.com

**Web page address**

**City**

Zahedan

**Province**

Sistan-va-Balouchestan

**Postal code**

9816743463

**Phone**

+98 915 952 2512

**Email**

sare4884@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Zahedan University of Medical Sciences

**Full name of responsible person**

Sareh Raeisi

**Position**

Student

**Latest degree**

A Level or less

**Other areas of specialty/work**

General Practitioner

**Street address**

Second Floor,Central Headquarters  
Building,Univercity of Medical Sciences  
Campus,Dr.Hesabi Square,Zahedan